Palazestrant is a small molecule commercialized by Olema Pharmaceuticals, with a leading Phase II program in Metastatic Breast Cancer. According to Globaldata, it is involved in 9 clinical trials, of which 4 are ongoing, and 5 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Palazestrant’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Palazestrant is expected to reach an annual total of $92 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Palazestrant (OP-1250) is under development for the treatment of metastatic HR positive and HER2 negative breast cancer, endometrial cancer, ER positive and HER2 positive breast cancer and gynaecological malignancies. It is administered by oral route in the form of pill. The drug candidate is a selective estrogen receptor degrader (SERD) and acts by targeting estrogen receptor (ESR).
Olema Pharmaceuticals Overview
Olema Pharmaceuticals (Olema Oncology) is a clinical-stage biopharmaceutical company that focused on the discovery, development and commercialization of next-generation targeted therapies for women’s cancers. The company lead product candidate, OP-1250, is a novel oral therapy with combined activity as both a complete ER antagonist. Olema Oncology is also evaluating OP-1250, an estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) in collaboration with Pfizer and Novartis HER2- metastatic breast cancer. Olema Oncology is headquartered in San Francisco, California, the United States.
The operating loss of the company was US$107 million in FY2022, compared to an operating loss of US$71.5 million in FY2021. The net loss of the company was US$104.8 million in FY2022, compared to a net loss of US$71.1 million in FY2021.
For a complete picture of Palazestrant’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.